🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Turkey / NCT07351682
Starting soon Observational

Antibacterial Activity of Calcium Hydroxide and Betamethasone in Apical Periodontitis

NCT07351682 · tracked via the Priya Life Science Turkey tracker
Sponsor
Duygu Degirmencioglu
Phase
Observational
Started
2026-03-01
Last updated
2026-01-20

Condition(s) studied

Apical Periodontitis

Study summary

Apical periodontitis is a chronic inflammatory disease caused by bacterial infection of the root canal system. Although mechanical cleaning and shaping reduce most microorganisms, bacteria may persist in areas that are difficult to reach, making the use of intracanal medicaments between treatment sessions clinically important.

Calcium hydroxide is one of the most commonly used intracanal medicaments because of its antibacterial properties. However, some resistant microorganisms, such as Enterococcus faecalis, may survive when calcium hydroxide is used alone. Therefore, combining calcium hydroxide with other agents, such as iodoform or corticosteroids, may improve its antibacterial effectiveness.

The purpose of this study is to compare the antibacterial activity of calcium hydroxide used alone or in combination with iodoform (Metapex) or betamethasone in patients with apical periodontitis. Bacterial load in root canals will be evaluated using droplet digital PCR (ddPCR), a highly sensitive molecular method that allows absolute quantification of bacteria. The results of this study are expected to provide evidence to support optimal intracanal medicament selection in endodontic retreatment cases.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * \- Adults aged 18 to 65 years. * Patients diagnosed with apical periodontitis requiring endodontic retreatment. * Presence of a single tooth with radiographic evidence of apical periodontitis. * Ability to provide written informed consent. Exclusion Criteria: * Use of systemic antibiotics within the previous 3 months. * Presence of systemic diseases that may affect healing or immune response. * Pregnancy or lactation. * Known allergy or hypersensitivity to any of the intracanal medicaments used. * Teeth with acute abscess, severe periodontal disease, or root fractures.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Istanbul Medipol University Faculty of Dentistry Istanbul Istanbul

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07351682 on ClinicalTrials.gov ↗ ← All trials in Turkey